Evolutionary trajectories and transmission dynamics of multidrug-resistant 1 Mycobacterium tuberculosis in Tibet, China 2 Qi Jiang<sup>1,2</sup>, Hai-can Liu<sup>3</sup>, Qing-yun Liu<sup>1,4</sup>, Jody E. Phelan<sup>5</sup>, Li Shi<sup>6</sup>, Min Gao<sup>3</sup>, Xiu-qin Zhao<sup>3</sup>, Jian Wang<sup>7</sup>, 3 Judith R. Glynn<sup>8</sup>, Chong-guang Yang<sup>9</sup>, Howard E. Takiff<sup>10, 11, 12</sup>, Kang-lin Wan<sup>3\*</sup>, Taane G. Clark<sup>5,8\*</sup>, Qian 4 Gao<sup>1\*</sup> 5 6 **Affiliations:** <sup>1</sup>Key Laboratory of Medical Molecular Virology, School of Basic Medical Sciences, Shanghai Medical College 7 and Shanghai Public Health Clinical Center, Fudan University, Shanghai, China 200032 8 9 <sup>2</sup> School of Health Sciences, Wuhan University, Wuhan, China 430071 <sup>3</sup> State Key Laboratory for Infectious Disease Prevention and Control and National Institute for Communicable 10 Disease Control and Prevention, Chinese Center for Disease Control and Prevention, Beijing, China 102206 11 <sup>4</sup> Department of Immunology and Infectious Diseases, Harvard T. H. Chan School of Public Health, Boston, 12 Massachusetts, USA 02115 13 <sup>5</sup> Department of Infection Biology, London School of Hygiene & Tropical Medicine, London, UK WC1E 7HT 14 <sup>6</sup> Tibet Autonomous Region People's Hospital, Lhasa, Tibet Autonomous Region, China 850000 15 <sup>7</sup> Tibet Center for Disease Control and Prevention, Lhasa, Tibet Autonomous Region, China 850000 16 <sup>8</sup> Department of Infectious Disease Epidemiology, London School of Hygiene & Tropical Medicine, London, UK 17 WC1E 7HT 18 <sup>9</sup> Department of Epidemiology of Microbial Diseases, Yale School of Public Health, Yale University, New Haven, 19 CT, USA 06510 20 <sup>10</sup> Integrated Mycobacterial Pathogenomics Unit, Institut Pasteur, Paris, France 75015 21 <sup>11</sup> Laboratorio de Genética Molecular, CMBC, IVIC, Caracas, Venezuela 22 <sup>12</sup> Shenzhen Nanshan Center for Chronic Disease Control, Shenzhen, China. 23 24 25 \* Corresponding authors Qian Gao, Key Laboratory of Medical Molecular Virology, School of Basic Medical Sciences, Fudan University, 26 Shanghai, China 200032; E-mail: qiangao@fudan.edu.cn 27 Taane G. Clark, London School of Hygiene & Tropical Medicine, London, United Kingdom WC1E 7HT; E-mail: 28 taane.clark@lshtm.ac.uk 29 Kanglin Wan, Chinese Center for Disease Control and Prevention, Beijing, China 102206; E-mail: 30 31 wankanglin@icdc.cn 32 Word counts: Abstract 250/250; Main text 3461/3500; Reference 26/40 33 34 Key words: Tuberculosis; Drug resistance; Transmission; Whole-genome sequencing; Phylodynamic analysis. 35 36

## 37 ABSTRACT

38 *Objective* Tibet has the highest prevalence of both tuberculosis disease and multidrug-resistant tuberculosis

39 (MDR-TB) in China. The circulated *Mycobacterium tuberculosis* strains from Tibet were sequenced to

40 investigate the underlying drivers for the high burden of MDR-TB.

41 *Methods* Using whole-genome sequencing data of 576 *M. tuberculosis* strains isolated from consecutive

patients in Tibet, we mapped resistance-conferring mutations onto phylogenetic trees to determine their
 evolution and spread. The impact of drug resistance on bacterial population growth was assessed with a

evolution and spread. The impact of drug resistance on bacterial population growth was assessed with a
Bayesian (Skyline Plot) analysis. Multivariable logistic regression was used to identify risk factors for the

- 45 development of rifampicin resistance.
- 46 *Results* Of the 576 isolates, 284 (49.3%), 280 (48.6%), and 236 (41.0%) were, respectively, genetically
- 47 resistant to isoniazid, rifampicin, or both (MDR-TB). Among the isoniazid- and rifampicin-resistant strains,
- the proportions in phylogenetically-inferred clusters were 77.8% (221/284) and 62.1% (174/280),
- 49 respectively. Nearly half (47.2%, 134/284) of the isoniazid-resistant strains were in six major clades, which
- 50 contained between 8 and 58 strains with *katG* S315T, *katG* S315N, or *fabG1* promoter -15 C>T resistance
- 51 mutations. These major clades exponentially expanded after emerging with isoniazid resistance and stabilized
- 52 before evolving into MDR-TB twenty years later. Isoniazid-resistant isolates showed an increased risk of
- accumulating rifampicin resistance compared to isoniazid-susceptible strains, with an adjusted odds ratio of
- 54 3.81 (95% confidence interval 2.47-5.95).
- 55 Conclusion Historical expansion of isoniazid-resistant strains and their increased likelihood of acquiring 56 rifampicin resistance both contributed to the high burden of MDR-TB in Tibet, highlighting the need to detect 57 INH-resistant strains promptly and to control their transmission.
- 58

## 60 INTRODUCTION

- 61 Drug resistance in *Mycobacterium tuberculosis* (*M. tuberculosis*) greatly hinders the control of tuberculosis
- disease (TB). Approximately half a million new TB cases with resistance to rifampicin (RIF, R) occurred
- 63 globally in 2019, of which 78% were also resistant to isoniazid (INH, H) and therefore multidrug-resistant
- $(MDR)^1$ . China has the second-largest percentage of global MDR-TB (14%), exceeded only by India (27%).
- In 2019, China had approximately 65,000 cases of MDR-TB, with high rates among both retreated (23%) and
- newly diagnosed TB cases  $(7.1\%)^1$ . Tibet (Xizang), an provincial autonomous region of China, has burdens of
- both TB and MDR-TB that are considerably higher than in other areas of China, with an estimated prevalence
- of TB that reached 758/100,000 population in  $2014^2$ . In the provincial capital city Lhasa, 21% of new and
- 69 57% of retreated cases had MDR-TB<sup>3</sup>.
- As Tibet is relatively isolated and historically has had limited population exchange with other parts of China,
- it seemed feasible to trace the evolution of drug resistance and transmission dynamics that shaped its high
- <sup>72</sup> burden of MDR-TB. To investigate the potential factors responsible for its high burden of MDR-TB, we
- vhole-genome sequenced both susceptible and resistant Tibetan *M. tuberculosis* isolates. The resulting
- sequence data were used to assess the level of *M. tuberculosis* transmission, to perform a phylodynamic
- analysis to reconstruct the evolution of drug resistance in the local clades and to determine the impact of drug
- resistance on the expansion of the bacterial populations.
- 77

#### 78 **METHODS**

#### 79 Study site and sampling

Tibet is located on the world's highest plateau, with an average altitude of over 4,000 metres above sea level. Its large expanse of 1.2 million square kilometres constitutes nearly an eighth of China's entire landmass but contains only 3.3 million inhabitants (< 3 people per square-kilometre). As part of a previous study<sup>4</sup>, a total of *576 M. tuberculosis* isolates were collected from consecutive patients with positive cultures at seven municipal-level clinics in Tibet over two periods -- during the years 2006, and 2009-2010. Genotyping of these isolates showed that the great majority (89%, 512/576) belonged to the Beijing lineage (Spoligotype

86 ST1 strains), with limited genetic diversity<sup>4</sup>.

## 87 Whole-genome sequencing and SNP calling

- 88 Genomic DNA of the *M. tuberculosis* isolates was extracted with the cetyltrimethylammonium bromide
- 89 (CTAB) method<sup>5</sup>. A 300-base-pair double-ended DNA library of each isolate was sequenced on the Illumina
- 90 HiSeq 2500 platform with an expected depth of 100-fold. Raw sequence reads were trimmed with Sickle
- software to remove reads of low quality (Phred base quality < 20 or read length < 10) and aligned to the
- 92 H37Rv reference genome (AL123456.3) using BWA-MEM. The SAMtools software suite was applied to the
- alignments to call single nucleotide polymorphisms (SNPs). Fixed mutations with a frequency  $\geq$ 75% were

<sup>94</sup> identified by VarScan. We defined genetic-clustered strains as those within a threshold genetic distance of

95 five or fewer  $SNPs^6$ .

### 96 Phylogeny construction and phylodynamic analysis

The identified SNPs were used to construct a phylogeny tree using RAxML software<sup>7</sup>, which implemented a 97 maximum-likelihood method with a general time-reversible model of nucleotide substitution with main node 98 values over 0.7 from 500 bootstrapping trees. Aligned sequences were also analysed using BEAST2 software 99 (version 2.6.1)<sup>8</sup> to construct a dated phylogeny based on a molecular clock with an uncorrelated log-normal 100 distribution and a tree prior using Coalescent Bayesian Skyline. The molecular clock was set at 1.14 (0.49-101 1.80 × 10<sup>-7</sup> substitutions per site per year, a mutation rate reported elsewhere for lineage 2 strains<sup>9</sup>. Bayesian 102 skyline plots for the effective population size were reconstructed in Tracer software<sup>10</sup>, with the age of the most 103 recent common ancestor (MRCA) node being the height of the tree. The phylogenies were visualized with 104

105 iTOL (version 5)<sup>11</sup>.

## 106 Determination of transmitted and acquired genotypic resistance

Known drug resistance mutations with a frequency  $\geq$  5% in the sequence alignments were identified using the 107 TB-profiler tool<sup>12</sup> based on a published database of mutations conferring resistance to 14 anti-TB drugs<sup>13</sup>. 108 Both transmitted and acquired resistance were determined by mapping these mutations onto a phylogenetic 109 tree<sup>14</sup> and defined by the following rules: mutations shared by all strains on a branch were considered to be 110 present at the MRCA of the branch and termed "transmitted resistance", and these strains were considered to 111 be phylogenetically clustered (phylo-clustered); while mutations on single branches and not present in 112 neighbouring branches were regarded as having occurred at the terminal tip and termed "acquired resistance". 113 To further investigate the population growth and resistance evolution for large drug-resistant phylo-clusters, 114 we also analysed strains on their neighbouring drug-sensitive sister branches that derived from the same 115

ancestral nodes in the phylogeny tree.

## 117 Data management and statistical analysis

A structured questionnaire obtained basic demographic and clinical information from enrolled patients after 118 they signed an informed consent form, which had been reviewed and approved by the Ethical Review Board 119 of the Chinese Center for Disease Control and Prevention (CDC). The data included: gender, age, occupation, 120 location of residence, sampling year, BCG vaccination, TB history and smear results. The anonymized data 121 were stored in Excel spreadsheets after double entry into EpiData (version 3.1). Univariable and multivariable 122 logistic regression were used to assess the association of risk factors for drug resistance and to estimate the 123 124 odds ratios (OR) and 95% confidence intervals (CIs). All statistical analyses were performed in R software (version 3.6.1). 125

126

### 127 **RESULTS**

#### 128 **Basic demographic and genetic characteristics**

A total of 576 clinical isolates were collected from pulmonary TB patients in Tibet during the years 2006 and 129 2009-2010. More than half (53.0%, 305/576) of the samples came from TB clinics in Lhasa, the provincial 130 capital, and the remainder from clinics in the other six administrative districts of Tibet (Suppl. Figure 1). 131 Among 561 patients for whom the survey data were available, 325 (58.0%) were male, the median age was 32

133 years (interquartile range 25-43), and 288 (51.3%) reported a previous history of TB treatment (Table 1).

The whole-genome sequences of the 576 M. tuberculosis clinical isolates had an average depth of 79-fold 134

(range 22- to 137-fold). A total of 2,433,862 SNPs were identified, of which 1,389 were resistance-conferring 135

- mutations across 14 anti-TB drugs. A maximum-likelihood phylogeny tree constructed using all SNPs 136
- (Figure 1) revealed that the great majority of isolates (524, 91.0%) belonged to Beijing Lineage 2, with a 137

minority belonging to the Euro-American Lineage 4 (36, 6.3%) or Central Asian Lineage 3 (16, 2.8%). From 138

the genotypic resistance profiles, 231 (40.1%) isolates were pan-susceptible while the other 345 (59.9%) 139

- 140 strains were resistant to at least one anti-TB drug, including 236 (41.0%) that were MDR-TB. The proportions of new and retreated patients with MDR-TB were 19.0% (52/273) and 60.4% (174/288), respectively (Table 141
- 1). 142

132

Although many studies have used thresholds between 5 and 12 SNPs to define a genetic cluster<sup>6,15</sup>, the Tibet 143 strains showed no clear separation but rather a gradual decrease in the distribution of the SNP differences 144 between strains (Figure 2). Using a limit of 5 SNPs to define clustered strains, Lineage 2 strains were nearly 145 twice as likely to be in genetic clusters (39.3%, 206/524) as the few Lineage 4 strains collected (22.2%, 8/36); 146 and MDR-TB strains showed significantly more clustering (47.0%, 111/236) than either pan-susceptible strains 147 148 (31.2%, 72/231) or those with other resistance profiles (30.3%, 33/109) (P<0.001) (Figure 2). The resistance profiles among different lineages did not show a significant difference (Suppl. Table 1). 149

#### Transmitted drug resistance 150

The mutations conferring drug resistance in *M. tuberculosis* strains have different fitness costs that can affect 151

their transmissibility<sup>16</sup>. Most INH-resistant strains carried the low-fitness cost katG S315T mutation and 152

showed a clustering rate of 41.8% (74/177), using the 5-SNP limit. Although strains carrying other INH-153

- resistance mutations were much less common, they all had higher clustering rates than the pan-sensitive 154
- strains, except for those with the katG S315N mutation (Table 2). Among 280 RIF-resistant strains, the most 155
- frequent mutation was the low-fitness cost rpoB S450L (99, 35.4%). The next most common was the rpoB 156
- H445Y (42, 15.0%) mutation and there were a few strains with two other substitutions of the same amino 157
- acid, all of which had higher clustering rates (rpoB H445Y/D/R, combined 51.3% [41/80]) than strains with 158
- rpoB S450L (37.4% [37/99]) (Table 2). 159
- Mapping the resistance-conferring mutations on the phylogenetic tree showed that 77.8% (221/284) of strains 160
- resistant to INH and 62.1% (174/280) resistant to RIF, belonged to phylo-clusters that resulted from the 161
- transmission of resistance mutations from parental strains (Table 2). Even higher proportions of strains 162

- resistant to SM (82.7%, 191/231) or PAS (96.0%, 72/75) resulted from transmitted resistance, as well as over 163
- half of strains resistant to the other first-line drugs ethambutol (EMB, E) (57.1%, 97/170) and pyrazinamide 164
- (PZA, Z) (52.1%, 63/121) (Suppl. Table 2). The sizes of the INH-resistant phylo-clusters were generally 165
- larger than those with RIF resistance (Table 2). There were four large phylo-clusters of strains with the katG 166
- S315T mutation, each containing more than ten strains, while the RIF resistant clusters had, at most, seven 167
- strains. To reconstruct the growth history of the bacterial population and the trajectories of resistance 168
- 169 accumulation, we focused on six large phylo-clusters that contained more than eight strains. In total, these six
- large phylo-clusters included nearly half of the INH-resistant isolates (47.2%, 134/284) or of the MDR-TB 170
- strains (48.7%, 115/236). For further analysis, each of these six phylo-clusters, together with their sister 171
- branches, were considered as clades, labelled A-F (Figure 1). 172

179

#### Evolutionary trajectories of drug resistance in the major clades 173

174 To determine when these six clades developed antibiotic resistance to each drug, we constructed dated

- phylogenetic trees for each, and estimated the evolutionary time to the appearance of nodes whose offspring 175
- strains all harboured the same resistance-conferring mutations. All of these clades first evolved INH resistance 176
- conferred by acquiring katG S315T (Clades B-E), katG S315N (Clade A) or fabG1 promoter -15 C>T (Clade 177
- 178 F) mutations, and subsequently evolved into phylo-clusters containing between 8 and 58 INH-resistant strains
- (Table 3). In five of these six clades, the mutations conferring INH resistance were acquired around year 1970 (95% CI 1967-1975), and the remaining Clade D acquired the katG S315T around 1989 (95% CI 1980-1998). 180
- Three clades (B, D and E) also acquired SM resistance at around the same time as INH resistance, and one 181
- clade (C) acquired additional resistance to PAS (Figure 3; Suppl. Figure 2). 182
- In all six clades, RIF resistance developed after 1990, much later than INH resistance and consistent with the 183
- time period in which RIF became widely used for treating TB in Tibet. Notably, each clade contained strains 184 185 with different RIF-resistance-conferring mutations, with no single mutation being dominant. Similarly, nearly
- all clades contained more than one mutation conferring resistance to the other first-line drugs EMB and PZA. 186
- After these clades developed INH resistance, mutations conferring RIF resistance occurred between 4 and 23 187
- times independently in different sub-clades, while EMB and PZA resistance occurred 2 to 13 times and 1 to 188
- 189 11 times, respectively (Table 3). Amongst all the sampled isolates, we identified 110 independent mutational
- 190 events for INH resistance and 161 for RIF resistance, among which 31.8% (35/110) and 34.8% (56/161),
- respectively, were transmitted to secondary strains in the phylo-clusters (Suppl. Table 2) 191
- Taking the largest clade, Clade C, as an example to illustrate the evolutionary trajectories in detail (Figure 3), 192
- all 58 phylo-clustered strains of Clade C carried the same mutations for INH (katG S315T) and PAS 193
- resistance (*thyX* promoter -16 C>T and *thyA* large segment deletion), both of which were estimated to have 194
- occurred around year 1968 (95% CI 1958-1977). Resistance to SM was subsequently acquired around year 195
- 1972, with simultaneous mutations of either rpsL K88R (1963-1980) or rpsL K43R (1962-1981), creating two 196
- sub-clades resistant to all drugs in the triple TB therapy used at the time (INH, SM and PAS). The mutations 197

198 conferring resistance to RIF occurred more than 20 years later on at least 23 descendent branches of this

clade, resulting in 12 RIF-resistant phylo-clusters of 2-6 strains, and another 11 non-clustered RIF-resistant

strains (**Figure 3**), indicating both acquired and transmitted resistance. Mutations conferring resistance to

EMB and PZA also developed independently on multiple branches, producing 19 strains that were resistant to

all four of the first-line drugs used in the standard HRZE therapy. Few strains belonging to this clade

203 developed resistance to second-line anti-TB drugs, including only eight pre-XDR-TB strains with

fluoroquinolones-resistant mutations in gyrA (90V, 94G, 94N) or gyrB (461N). The other clades underwent

similar trajectories, acquiring mutations conferring resistance to RIF and other first-line drugs multiple times

in parallel in the descendants of strains with pre-existing INH resistance (Suppl. Figure 2).

207

## 208 Risk of INH resistance for population expansion and resistance accumulation

To evaluate the impact of INH and RIF resistance on the clonal expansion of local TB strains, we used 209 Bayesian skyline plots to reconstruct the growth of the bacterial populations in the six major clades (Figure 210 211 4). Before the emergence of drug resistance, mainly resistance to INH, the bacterial population of these clades showed varied patterns of expansion or shrinkage. Irrespective of their previous patterns however, after the 212 development of INH resistance there followed a period of exponential growth during which the bacterial 213 populations of these clades expanded for decades. Subsequently, after the acquisition of RIF resistance, the 214 population of most clades stabilized (Clade E) or decreased (Clades A, B, D, F) (Figure 4), and only Clade C 215 continued to expand while acquiring many RIF-resistance mutations independently on multiple branches. 216

We suspected that strains with pre-existing INH resistance would be more likely to accumulate mutations 217 conferring RIF resistance than INH-sensitive strains. For example, 87.9% (51/58) of the INH-resistant Clade 218 C strains acquired RIF resistance, compared to only 19.2% (5/26) of strains on its sister INH-sensitive 219 branches (Figure 3). To quantify the effect of pre-existing INH resistance on the accumulation of RIF 220 resistance, we tested it as an independent variable in a logistic regression model with the whole dataset. In the 221 univariable analysis, the development of RIF resistance was significantly associated with strains that had pre-222 existing INH resistance, belonged to a genetic cluster (genetic distance  $\leq$  5 SNPs), were isolated from 223 retreated patients, were isolated in Lhasa, or were sampled in 2006 rather than in 2009/2010 (Table 4). These 224 variables were then included in a multivariable logistic regression, adjusting for age and gender and excluding 225 cases with missing data. The final model showed that, M. tuberculosis strains with pre-existing INH resistance 226 had an adjusted odds ratio of developing RIF resistance of 3.81 (95% CI: 2.47-5.95) compared to INH-227 susceptible strains, and genetic-clustered strains within a 5-SNP distance had an adjusted odds ratio of 2.08 228 (95% CI:1.37-3.18) compared to non-clustered strains (Table 4). 229

230

## 231 DISCUSSION

232 In this study of *M. tuberculosis* isolates from Tibet, China, we characterized evolutionary trajectories for

- 233 MDR-TB and demonstrated a high level of transmitted resistance to both INH and RIF drugs. However, six
- clades were shown to expand exponentially after acquiring INH-resistance mutations in the 1970s, and mostly
- stabilized before accumulating multiple RIF-resistance mutations to become MDR-TB in the late 1990s.
- 236 Compared to INH-susceptible strains, strains with mutations conferring INH resistance were found to have a
- 237 significantly higher risk of acquiring RIF resistance. Both the historical expansion of INH-resistant strains and
- the increased risk of these strains acquiring additional RIF resistance likely contributed to the current high
- 239 burden of MDR-TB in Tibet.
- The rate of genotypic drug-resistance among sampled *M. tuberculosis* isolates in Tibet was extremely high, 240 241 with 59.9% of isolates resistant to any anti-TB drug, and 41.0% MDR-TB. Recent transmission contributed 242 almost half (47.0%) of the MDR-TB cases, using the genetic-clustering threshold of 5 SNPs. This proportion increased to 69.1% when the genetic-clustering threshold was set at 12 SNPs. The level of recent transmission 243 of MDR-TB in Tibet was much higher than that in other areas of China, such as Shanghai<sup>15</sup> or Shenzhen<sup>17</sup> 244 (32% and 25%, respectively, with a 12-SNP threshold,), and was similar to the proportions of MDR-TB 245 attributed to recent transmission in other countries with high MDR-TB burdens, such as Russia (60% with 246 terminal branch length of  $\leq 5$  SNPs)<sup>14</sup> or South Africa (79% in phylogenetic clades)<sup>18</sup>. However, while the 247 majority of the MDR-TB burden in these other countries is caused by a few MDR strains that are extensively 248 transmitted, most MDR-TB strains in Tibet belonged to small genetic-clusters of only 2 to 6 cases. We thus 249 speculate that the high prevalence of MDR-TB in Tibet is more likely the result of poor TB control than the 250 high transmissibility of particular strains. Due to relatively poor healthcare infrastructure in Tibet, the 251 proportion of TB cases tested for drug resistance was low. The Tibet CDC reported that between July 2017 252 and June 2018, only 8 out of 476 (1.8%) smear-positive TB cases were tested for drug sensitivity and just one 253 MDR-TB case was diagnosed. The underdiagnosis of MDR-TB in Tibet could result in inappropriate 254 treatment regimens, poor treatment outcomes and prolonged transmission of MDR-TB strains. 255
- We could phylogenetically follow the progression from INH-resistant TB to MDR-TB through the acquisition 256 of mutations conferring RIF resistance, especially within the six major clades. We showed that strains with 257 pre-existing INH resistance were more likely to develop RIF resistance, which is consistent with an in vitro 258 experimental study<sup>19</sup> that showed that laboratory-generated INH-resistant strains were more likely to 259 accumulate RIF-resistant mutations than INH-sensitive strains. In a real-world dataset, a recent meta-analysis 260 similarly found that treatment of INH-resistant, RIF-sensitive strains with the standard first-line HRZE 261 regimen resulted in high proportions of unfavourable outcomes, including relapse or treatment failure rate 262 (15%) and development of MDR-TB  $(3.6\%)^{20}$ . A recent study<sup>21</sup> highlighted the high global prevalence of 263 INH-resistant TB, with proportions among new and retreated patients of 7.4% and 11.4%, respectively. If 264 undetected and treated with ineffective regimens, these numerous INH-resistant strains could be transmitted 265 266 during prolonged infections, with an increased likelihood of acquiring further resistance.
- INH resistance is thought to evolve earlier than resistance to the other first-line drugs. A study<sup>22</sup> using a large global dataset of *M. tuberculosis* whole-genome sequences found that the INH-resistance mutation katG

S315T overwhelmingly arose before RIF resistance across different lineages and regions. In our study, four of 269 the six large clades were found to have first acquired the katG S315T mutation, and one clade each acquired 270 the katG S315N and fabG1 promoter -15 C>T mutations. The INH resistance impaired the effectiveness of 271 triple therapy that was being prescribed at the time, and from the 1970s to 1990s these clades evolved into 272 large phylo-clusters before RIF, EMB and PZA were introduced into TB treatment in Tibet. From the 273 phylogenetic trees, we could see that the mutations conferring RIF resistance then occurred independently, in 274 275 parallel, on multiple branches of these INH-resistant clades, and subsequently disseminated to cause large numbers of MDR-TB cases. This pattern differs from several MDR-TB outbreaks reported elsewhere that 276 were caused by the extensive transmission of a very few dominant MDR-TB strains<sup>14,23</sup>. In a huge outbreak 277 over four decades in Argentina<sup>24</sup>, RIF resistance was acquired soon after the development of INH resistance. 278 In London<sup>25</sup>, an MDR-TB outbreak was found to have originated from an INH-resistant strain, but RIF 279 resistance was acquired only once during transmission. The specific pattern for multiple, independent 280 acquisitions of RIF resistance among *M. tuberculosis* in Tibet may be a result of the historical expansion of 281 INH-resistant strains before the implementation of RIF. 282

283 Half of the samples included in this study came from retreated TB patients, a proportion higher than the usual rate, but the overall retreatment rate of TB in Tibet is much higher than in other regions of China. According 284 to a cross-sectional investigation by Tibet CDC in 2014<sup>26</sup>, the proportion of retreated patients reached 37.5% 285 in Lhasa, and averaged 26.6% in other Tibetan cities. The high percentage of retreated patients in this study 286 could also partially result from sampling bias at the municipal general hospitals, where the cultures available 287 288 for this study were more likely to have been obtained from severe and refractory cases. Correspondingly, the drug-resistance rates in this study are also higher than the average resistance rates in Tibet. However, the 289 overrepresentation of resistant strains should not affect our characterization of the evolution of drug 290 resistance, the history of bacterial population expansion and the contribution of drug resistant strains to the 291 292 current TB epidemic in Tibet. Although we found a very high proportion of clustering and inferred 293 transmission of drug-resistant strains, it is likely that these are underestimates, because our sample contained only about one-fifth of the culture-confirmed TB patients in Tibet during only the two short periods of time 294 included in the study. 295

In conclusion, the high proportion of clustering suggests that there is considerable transmission of drug
resistant *M. tuberculosis* in Tibet. The expansion of INH resistant clades from the 1970's through the 1990's
and their increased propensity to acquire RIF resistance likely contributed to the current MDR-TB burden.
Pragmatic strategies should be implemented for the early detection and effective treatment of both INH and
RIF resistant strains.

301

Contribution: QJ, KLW, and QG designed the study. HCL, LS, MG, XQZ, and JW collected the samples and
 data. QJ, QYL, and JEP analysed the data. TGC guided the genomic analysis. JRG and CGY suggested in the

epidemiological analysis. QJ, HET, QG drafted the article. All the authors contributed to the manuscript and
 reviewed the final version.

306 **Acknowledgements** We thank the physicians and technicians of Tibetan CDC and Chinese CDC for the 307 collection, culture and storage of clinical samples, and the conduction of the epidemiological review.

**Funding:** This work was supported by the National Major Science and Technology Project of China

309 [2017ZX10201302-006 and 2018ZX10715012-005 to QG, and 2018ZX10101002 to KLW]; and the Natural
 310 Science Foundation of China [91631301 and 81661128043 to QG].

Science Foundation of China [91631301 and 81661128043 to QG].

311 **Disclaimer:** The funders had no role in study design, data collection and analysis, decision to publish, or 312 preparation of the manuscript.

- 313 **Competing interests:** We declare no competing interests.
- 314 **Patient consent for publication:** Not required.

Ethics approval: Ethical approval was obtained from the Ethical Review Board of the Chinese Center for
 Disease Control and Prevention.

- 317 Data availability statement: Sequencing reads are deposited in the NCBI (EMBL-EBI) under study
   318 accession number SRP276868.
- 319

320

# 321 **REFERENCE**

- World Health Organization. Global Tuberculosis Report 2020. Geneva: World Health Organization,
   2020.
- Li B, Zhang X, Guo J, *et al.* Prevalence of pulmonary tuberculosis in Tibet Autonomous Region,
   China, 2014. *Int J Tuberc lung Dis* 2019; 23: 735–40.
- 3 Yang J, Yangla, Bassan-Junda, Li C, Du B. Analysis on the drug resistance of *Mycobacterium tuberculosis* in Lhasa area, Tibet. *J Tibet Univ (in Chinese)* 2014; 29: 36–9.
- 4 Dong H, Shi L, Zhao X, *et al.* Genetic diversity of *Mycobacterium tuberculosis* isolates from Tibetans
   in Tibet, China. *PLoS One* 2012; 7: e33904.
- Schiebelhut LM, Abboud SS, Gomez Daglio LE, Swift HF, Dawson MN. A comparison of DNA
   extraction methods for high-throughput DNA analyses. *Mol Ecol Resour* 2017; 17: 721–9.
- 332 6 Walker TM, Ip CL, Harrell RH, et al. Whole-genome sequencing to delineate Mycobacterium

333		tuberculosis outbreaks: a retrospective observational study. Lancet Infect Dis 2013; 13: 137–46.
334 335	7	Stamatakis A. RAxML version 8: a tool for phylogenetic analysis and post-analysis of large phylogenies. <i>Bioinformatics</i> 2014; <b>30</b> : 1312–3.
336 337	8	Bouckaert R, Vaughan TG, Barido-Sottani J, <i>et al.</i> BEAST 2.5: An advanced software platform for Bayesian evolutionary analysis. <i>PLoS Comput Biol</i> 2019; <b>15</b> : e1006650–e1006650.
338 339	9	Menardo F, Duchene S, Brites D, Gagneux S. The molecular clock of <i>Mycobacterium tuberculosis</i> . <i>PLoS Pathog</i> 2019; <b>15</b> : e1008067.
340 341	10	Rambaut A, Drummond AJ, Xie D, Baele G, Suchard MA. Posterior Summarization in Bayesian Phylogenetics Using Tracer 1.7. <i>Syst Biol</i> 2018; <b>67</b> : 901–4.
342 343	11	Letunic I, Bork P. Interactive tree of life (iTOL) v3: an online tool for the display and annotation of phylogenetic and other trees. <i>Nucleic Acids Res</i> 2016; <b>44</b> : W242–5.
344 345	12	Phelan JE, O'Sullivan DM, Machado D, <i>et al.</i> Integrating informatics tools and portable sequencing technology for rapid detection of resistance to anti-tuberculous drugs. <i>Genome Med</i> 2019; <b>11</b> : 41.
346 347	13	Coll F, Phelan J, Hill-Cawthorne GA, <i>et al.</i> Genome-wide analysis of multi- and extensively drug-resistant <i>Mycobacterium tuberculosis</i> . <i>Nat Genet</i> 2018; <b>50</b> : 307–16.
348 349	14	Casali N, Nikolayevskyy V, Balabanova Y, <i>et al.</i> Evolution and transmission of drug-resistant tuberculosis in a Russian population. <i>Nat Genet</i> 2014; <b>46</b> : 279–86.
350 351 352	15	Yang C, Luo T, Shen X, <i>et al.</i> Transmission of multidrug-resistant <i>Mycobacterium tuberculosis</i> in Shanghai, China: a retrospective observational study using whole-genome sequencing and epidemiological investigation. <i>Lancet Infect Dis</i> 2017; <b>17</b> : 275–84.
353 354	16	Gygli SM, Borrell S, Trauner A, Gagneux S. Antimicrobial resistance in <i>Mycobacterium tuberculosis</i> : mechanistic and evolutionary perspectives. <i>FEMS Microbiol Rev</i> 2017; <b>41</b> : 354–73.
355 356 357	17	Jiang Q, Liu Q, Ji L, <i>et al.</i> Citywide transmission of MDR-TB under China's rapid urbanization: a retrospective population-based genomic spatial epidemiological study. <i>Clin Infect Dis</i> 2020; <b>71</b> : 142–51.
358 359	18	Brown TS, Challagundla L, Baugh EH, <i>et al.</i> Pre-detection history of extensively drug-resistant tuberculosis in KwaZulu-Natal, South Africa. <i>Proc Natl Acad Sci U S A</i> 2019; <b>116</b> : 23284–91.
360 361 362	19	Bergval I, Kwok B, Schuitema A, <i>et al.</i> Pre-existing isoniazid resistance, but not the genotype of <i>Mycobacterium tuberculosis</i> drives rifampicin resistance codon preference in vitro. <i>PLoS One</i> 2012; 7: e29108.
363 364 365	20	Gegia M, Winters N, Benedetti A, van Soolingen D, Menzies D. Treatment of isoniazid-resistant tuberculosis with first-line drugs: a systematic review and meta-analysis. <i>Lancet Infect Dis</i> 2017; <b>17</b> : 223–34.

366 367	21	Dean AS, Zignol M, Cabibbe AM, <i>et al.</i> Prevalence and genetic profiles of isoniazid resistance in tuberculosis patients: A multicountry analysis of cross-sectional data. <i>PLoS Med</i> 2020; <b>17</b> : e1003008.
368 369 370	22	Manson AL, Cohen KA, Abeel T, <i>et al.</i> Genomic analysis of globally diverse <i>Mycobacterium tuberculosis</i> strains provides insights into the emergence and spread of multidrug resistance. <i>Nat Genet</i> 2017; <b>49</b> : 395–402.
371 372 373	23	Cohen KA, Abeel T, Manson McGuire A, <i>et al.</i> Evolution of Extensively Drug-Resistant Tuberculosis over Four Decades: Whole Genome Sequencing and Dating Analysis of <i>Mycobacterium tuberculosis</i> Isolates from KwaZulu-Natal. <i>PLoS Med</i> 2015; <b>12</b> : e1001880.
374 375	24	Eldholm V, Monteserin J, Rieux A, et al. Four decades of transmission of a multidrug-resistant <i>Mycobacterium tuberculosis</i> outbreak strain. <i>Nat Commun</i> 2015; <b>6</b> : 7119.
376 377 378	25	Casali N, Broda A, Harris SR, Parkhill J, Brown T, Drobniewski F. Whole Genome Sequence Analysis of a Large Isoniazid-Resistant Tuberculosis Outbreak in London: A Retrospective Observational Study. <i>PLoS Med</i> 2016; <b>13</b> : e1002137.
379 380	26	Tibet CDC. The third epidemiological sampling survey of tuberculosis in Tibet Autonomous Region in 2014 (in Chinese). 2014.
381		

383Table 1. Basic demographic characteristics of tuberculosis patients in Tibet and the genetic characteristics of

	Total	New cases	Retreated cases	. 2	D 1
	N=576	N=273	N=288	χ-	P value
Median Age (IQR), years	32 (25-43)	32 (23-44)	33 (26-43)	1.12	0.263
Gender, n (%)				4.12	0.042
Male	325 (58.0)	146 (53.5)	179 (62.2)		
Female	235 (42.0)	126 (46.2)	109 (37.8)		
Occupation				22.67	< 0.001
Farmer	298 (53.1)	146 (53.5)	152 (52.8)		
Worker	43 (7.7)	20 (7.3)	23 (8.0)		
Student	55 (9.8)	42 (15.4)	13 (4.5)		
Other	180 (31.3)	65 (23.8)	100 (34.7)		
Location, n (%)				9.30	0.002
Lhasa	305 (53.1)	164 (60.1)	136 (47.2)		
Other	271 (47.0)	109 (39.9)	152 (52.8)		
Sample year, n (%)				0.46	0.794
2006	177 (30.7)	81 (30.0)	82 (28.5)		
2009	172 (30.0)	80 (29.3)	92 (31.9)		
2010	227 (39.4)	112 (41.0)	114 (39.6)		
Smear status				12.29	0.006
Negative or scanty	245 (42.5)	137 (50.2)	108 (37.5)		
1+	142 (25.3)	68 (24.9)	74 (25.7)		
2+	94 (16.8)	34 (12.5)	60 (20.8)		
3+	80 (14.3)	34 (12.5)	46 (16.0)		
Lineage, n (%)				0.26	0.878
Lineage 2	524 (91.0)	247 (90.5)	264 (91.7)		
Lineage 4	36 (6.3)	18 (6.6)	17 (5.9)		
Lineage 3	16 (2.8)	8 (2.9)	7 (2.4)		
Genetic resistance, n (%)				106.99	< 0.001
Pan-susc.	231 (40.1)	160 (58.6)	67 (23.3)		
DR	109 (18.9)	61 (22.3)	47 (16.3)		
MDR	187 (32.5)	42 (15.4)	136 (47.2)		
Pre-XDR	41 (7.1)	10 (3.7)	31 (10.8)		
XDR	8 (1.4)	0 (0)	7 (2.4)		
Genetic clustering, n (%)					
1-SNP	105 (18.2)	44 (16.1)	57 (19.8)	1.28	0.258
5-SNP	216 (37.5)	93 (34.1)	118 (41.0)	2.85	0.091
12-SNP	339 (58.9)	153 (56.0)	176 (61.1)	1.48	0.223
25-SNP	444 (77.1)	208 (76.2)	222 (77.1)	0.06	0.803
50-SNP	509 (88.4)	238 (87.2)	257 (89.2)	0.57	0.450

384 their clinical isolates, stratified by tuberculosis treatment history

385 Abbreviations: IQR=interquartile range; Pan-susc. = pan-susceptible; DR = Drug Resistant but not MDR-TB; MDR-TB = MultiDrug-

Resistant tuberculosis; XDR = eXtensively Drug-Resistant; SNP = single nucleotide polymorphism.

387 Note: Demographic data (tuberculosis treatment history, age and gender) was missing for 16 cases.

389 Table 2. Genetic and phylogenetic clustering of *M. tuberculosis* strains with the principal mutations

Profile/mutation	Sum, n (%)	5-SNP clustering, n (%)	12-SNP clustering, n (%)	Phylo- clustering, n (%)	Phylo-cluster size, median (range)
Resistance profile					
Pan-Susceptible	231 (40.1)	72 (31.2)	121 (52.4)	-	-
Resistant TB	109 (18.9)	33 (30.3)	55 (50.5)	-	-
MDR-TB	236 (41.0)	111 (47.0)	163 (69.1)	-	-
INH resistance					
Total resistant	284 (100.0)	124 (43.7)	190 (66.9)	221 (77.8)	-
katG S315T	177 (62.3)	74 (41.8)	125 (70.6)	155 (87.6)	8.6 (2-58)
<i>fabG1</i> -15 C>T	28 (9.9)	17 (60.7)	21 (75.0)	24 (85.7)	4.8 (2-12)
katG S315N	19 (6.7)	4 (21.1)	8 (42.1)	13 (68.4)	4.3 (2-8)
<i>ahpC</i> -52 C>T	12 (4.2)	8 (66.7)	9 (75.0)	7 (58.3)	3.5 (2-8)
katG deletion	10 (3.5)	8 (80.0)	8 (80.0)	8 (80.0)	2.7 (2-3)
RIF resistance					
Total resistant	280 (100.0)	126 (45.0)	185 (66.1)	174 (62.1)	-
rpoB S450L	99 (35.4)	37 (37.4)	58 (58.6)	59 (59.6)	3.1 (2-7)
<i>гроВ</i> Н445Ү	42 (15.0)	22 (52.4)	28 (68.3)	28 (68.3)	4.0 (2-6)
rpoB L452P	25 (8.9)	6 (24.0)	13 (52.0)	9 (36.0)	2.3 (2-3)
rpoB L430P	23 (8.2)	11 (47.8)	17 (73.9)	17 (73.9)	3.4 (2-4)
<i>rpoB</i> H445D	22 (7.9)	11 (50.0)	16 (72.7)	15 (68.2)	3.0 (2-4)
<i>rpoB</i> H445R	16 (5.7)	8 (50.0)	13 (81.3)	11 (68.8)	3.7 (2-6)

390 conferring isoniazid (INH) or rifampicin (RIF) resistance

391 Abbreviations: TB=tuberculosis; MDR-TB = MultiDrug-Resistant tuberculosis; INH, isoniazid; RIF, rifampicin; SNP = single

392 nucleotide polymorphism.

Clade	Initial resistance mutation	Estimated year of first INH resistance	# phylo-clustered strains (+ # sister branchec) INH SM PAS RIF E			nutation EMB	accumula PZA	Resistant to # drugs				
		(95% credible intervals)	branches)		51.1	1110	141	Emb	1	- 4	82D	per strain
Clade A	katG S315N	1972.81 (1957.70-1986.26)	8 (+4)	8/1	7/4	0	6/4	3/2	2/2	0	0	3.3
Clade B	katG S315T	1975.36 (1961.07-1987.82)	12 (+10)	12/2	12/1	2/1	9/4	9/3	6/1	3/2	0	4.8
Clade C	katG S315T	1967.55 (1957.58-1977.10)	58 (+26)	58/1	58/2	58/1	51/23	35/13	21/11	8/6	0	5.0
Clade D	katG S315T	1989.69 (1980.47-1998.02)	13 (+3)	13/1	13/1	4/2	11/4	3/4	4/1	4/1	3/1	4.2
Clade E	katG S315T	1973.72 (1964.21-1983.33)	31 (+0)	31/1	31/1	0	26/14	16/11	7/5	7/6	4/3	4.2
Clade F	<i>fabG1</i> promoter -15 C>T	1969.29 (1954.49-1982.62)	12 (+1)	12/4	3/3	0	12/9	10/9	6/3	0	3/3	4.2

Table 3. Accumulation of mutations conferring drug resistance for anti-tuberculosis drugs among the six major clades A-F

Abbreviations: INH, isoniazid; SM, streptomycin; PAS, P-aminosalicylic acid; RIF, rifampicin; EMB, ethambutol; PZA, pyrazinamide; FQ, fluoroquinolones; SLD, second-line injectable drugs (amikacin, kanamycin, capreomycin).

	RIF-resistant strains	RIF-sensitive strains	Univariable regression		Multivariable regression		
	N=280, m±sd/n (%)	N=296, m±sd/n (%)	Unadjusted odds ratio (95%CI)	P value	Adjusted odds ratio (95%CI)	P value	
Age, years*	$33.8 \pm 14.7$	$34.7 \pm \! 15.6$	1.00 (0.99-1.01)	0.481	1.00 (0.99-1.01)	0.899	
Male Gender*	160 (59.5)	165 (56.7)	1.12 (0.80-1.57)	0.506	0.93 (0.61-1.41)	0.731	
Sampled in Lhasa	127 (45.4)	173 (58.4)	0.62 (0.44-0.86)	0.004	0.72 (0.48-1.08)	0.109	
Sampled in 2006	98 (35.0%)	79 (26.7)	1.48 (1.04-2.11)	0.031	1.74 (1.11-2.74)	0.016	
Clustering $\leq 5$ SNPs	126 (45.0)	90 (30.4)	1.87 (1.33-2.64)	< 0.001	2.08 (1.37-3.18)	0.001	
Pre-existing isoniazid resistance	135 (48.2)	58 (19.6)	3.82 (2.65-5.56)	< 0.001	3.81 (2.47-5.95)	< 0.001	
TB history*	205 (76.2)	83 (28.4)	8.07 (5.55-11.85)	< 0.001	8.14 (5.43-12.38)	< 0.001	

Table 4. Risk factors for the development of rifampicin (RIF) resistance in univariable and multivariable logistic regression models

Note: \*Demographic data was missing for 16 cases, which were excluded from the multivariable regression.

## **FIGURE LEGENDS**

**Figure 1. Genetic structure of prevalent** *M. tuberculosis* **in Tibet.** The maximum-likelihood phylogeny tree of 576 *M. tuberculosis* clinical isolates sampled during years 2006 and 2009-2010 in Tibet, was rooted at midpoint with key nodes gaining a bootstrap value over 0.7. Bootstrap values are shown as numbers on major nodes. Coloured branches show three identified lineages: Beijing strains (Lineage 2, L2) in blue, (Modern Beijing sub-lineage L2.3 in light blue), Central Asian Strain (CAS) (L3) in purple, and Euro-American lineage (L4) in orange. The innermost surrounding circle indicates the genotypic resistance profile of each strain, including pan-susceptible (white), drug-resistant (yellow), MDR (orange), and XDR strains (black). The outermost surrounding circles indicate genetic clustering with thresholds of 1-, 5-, 12-, and 25-SNP distances. Major drug-resistant clades are labelled A-F.

**Figure 2. Distribution of minimum genetic distance and accumulated clustering rates overall, and stratified by strain lineage and drug resistance profile.** Vertical lines indicate the proportions of strains in 5-SNP, 12-SNP, 25-SNP and 50-SNP clusters, respectively. "Drug-resistant" means drug-resistant tuberculosis but not MDR-TB. Most strains (88.4%, 509/576) were separated from another strain by no more than 50 SNPs, and the proportions of strains separated by up to 5, 12 or 25 SNPs from another isolate were 27.5%, 58.9% and 77.1%, respectively.

**Figure 3. Determination of acquisition or transmission of resistance-conferring mutations.** The left side shows a dated phylogeny tree of Clade C, with blue and red branches indicating transmitted resistance to INH and RIF, respectively. The right side shows various resistance mutations in different panels with colors indicating resistance to the corresponding drugs, as labelled above. The blue arrow points to nodes where INH resistance mutations occurred with the approximate dates in blue, while red arrows and dates indicate the occurrence of RIF-resistance mutations transmitted to three or more strains. Abbreviations: INH, isoniazid; SM, streptomycin; PAS, P-aminosalicylic acid; RIF, rifampicin; EMB, ethambutol; PZA, pyrazinamide; FQ, fluoroquinolones

**Figure 4. The effective population size of the six large clades A-F.** Blue and red dash lines indicating the acquisition of isoniazid (INH) and rifampicin (RIF) mutations, respectively. Note, the scales vary.





Number of clustered strains

Minimum genetic distance (SNPs)



-100 -75 -50 -25

